Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Launching: Thursday 12th December 2024
ADVANCED SEARCH
Log in
Top
Annals of Nuclear Medicine

Open Access 05-11-2024 | Thyroid Cancer | Review Article

Research trends and hotspots of radioiodine-refractory thyroid cancer treatment in the twenty-first century: a bibliometric analysis

Authors: Yuhang Xue, Yuzhe Zhang, Xintao Ding, Xinyu Wu, Bo Li, Ye Zhang, Yongju Gao

Published in: Annals of Nuclear Medicine

Login to get access

Abstract

The treatment of radioiodine-refractory differentiated thyroid cancer (RAIR-DTC) has made significant advancements in the twenty-first century. This study aimed to assess the current state of research and identify potential new directions by conducting a bibliometric analysis of scientific publications on RAIR-DTC treatment. Publications relevant to RAIR-DTC, published from January 1, 2000, to December 31, 2023, were retrieved from the Web of Science Core Collection. Bibliometric analyses of major keywords, authors, countries, institutions, publications, and journals were conducted using CiteSpace and VOSviewer. A total of 859 papers were included in the analysis. The results demonstrated a rising trend in the number of publications over time. The United States was identified as the leading contributor in terms of publication output, citations, and international collaborations. Gustave Roussy emerged as the top organization in publication productivity, while the journal Thyroid had the highest number of related publications. The research on RAIR treatment was categorized into three key hotspots: clinical trials of targeted therapies, novel therapeutic strategies, and debates surrounding the RAIR-DTC management. RAIR-DTC research is expanding from the clinical trial phase of tyrosine kinase inhibitor monotherapy to a more complex combination therapy strategy, in particular, the synergistic effect of immune checkpoint inhibitors and other therapeutic agents, requiring more high-quality prospective studies to validate the clinical benefits. Moreover, the timely identification of RAIR-DTC patients holds the potential to enable early disease intervention, constituting a pivotal novel research direction in the future.
Literature
1.
2.
Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA. 2017;317:1338.PubMedPubMedCentralCrossRef
3.
Agrawal N, Akbani R, Aksoy BA, Ally A, Arachchi H, Asa SL, et al. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159:676–90.PubMedCentralCrossRef
4.
Viola D, Valerio L, Molinaro E, Agate L, Bottici V, Biagini A, et al. Treatment of advanced thyroid cancer with targeted therapies: ten years of experience. Endocr Relat Cancer. 2016;23:R185-205.PubMedCrossRef
5.
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133.PubMedPubMedCentralCrossRef
6.
Lundgren CI, Hall P, Ekbom A, Frisell J, Zedenius J, Dickman PW. Incidence and survival of Swedish patients with differentiated thyroid cancer. Int J Cancer. 2003;106:569–73.PubMedCrossRef
7.
8.
Schlumberger M, Brose M, Elisei R, Leboulleux S, Luster M, Pitoia F, et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endo. 2014;2:356–8.CrossRef
9.
Karapanou O, Simeakis G, Vlassopoulou B, Alevizaki M, Saltiki K. Advanced RAI-refractory thyroid cancer: an update on treatment perspectives. Endocr Relat Cancer. 2022;29:R57-66.PubMedCrossRef
10.
11.
12.
Widakowich C, De Castro G, De Azambuja E, Dinh P, Awada A. Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist. 2007;12:1443–55.PubMedCrossRef
13.
Simon D, Körber C, Krausch M, Segering J, Groth P, Görges R, et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med. 2002;29:775–82.CrossRef
14.
Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med. 2013;368:623–32.PubMedPubMedCentralCrossRef
15.
Dunn LA, Sherman EJ, Baxi SS, Tchekmedyian V, Grewal RK, Larson SM, et al. Vemurafenib redifferentiation of BRAF mutant, RAI-Refractory thyroid cancers. J Clin Endocr Metab. 2019;104:1417–28.PubMedCrossRef
16.
Rothenberg SM, McFadden DG, Palmer EL, Daniels GH, Wirth LJ. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. Clin Cancer Res. 2015;21:1028–35.PubMedCrossRef
17.
Turner N, Hamidi S, Ouni R, Rico R, Henderson YC, Puche M, et al. Emerging therapeutic options for follicular-derived thyroid cancer in the era of immunotherapy. Front Immunol. 2024;15:1369780.PubMedPubMedCentralCrossRef
18.
Xia M, Wang S, Ye Y, Tu Y, Huang T, Gao L. Effect of the m6ARNA gene on the prognosis of thyroid cancer, immune infiltration, and promising immunotherapy. Front Immunol. 2022;13: 995645.PubMedPubMedCentralCrossRef
19.
Wu P, Shi J, Wang Z, Sun W, Zhang H. Evaluate the immune-related eRNA models and signature score to predict the response to immunotherapy in thyroid carcinoma. Cancer Cell Int. 2022;22:307.PubMedPubMedCentralCrossRef
20.
21.
Song B, Lin Z, Feng C, Zhao X, Teng W. Global research landscape and trends of papillary thyroid cancer therapy: a bibliometric analysis. Front Endocrinol. 2023;14:1252389.CrossRef
22.
Van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84:523–38.PubMedCrossRef
23.
24.
25.
Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372:621–30.PubMedCrossRef
26.
Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384:319–28.PubMedPubMedCentralCrossRef
27.
Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008;26:4714–9.PubMedPubMedCentralCrossRef
28.
29.
Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT. Cancer Res. 2009;69:4885–93.PubMedPubMedCentralCrossRef
30.
Haugen BR. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: what is new and what has changed? Cancer. 2017;123:372–81.PubMedCrossRef
31.
Sa R, Xu Y, Pan X, Wang Y, Lin Z, Zhang X, et al. A bibliometric analysis of research progress on pharmacovigilance and cancer from 2002 to 2021. Front Oncol. 2023;13:1078254.PubMedPubMedCentralCrossRef
32.
Cabanillas ME, Schlumberger M, Jarzab B, Martins RG, Pacini F, Robinson B, et al. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessment. Cancer. 2015;121:2749–56.PubMedCrossRef
33.
Tahara M, Takami H, Ito Y, Okamoto T, Sugitani I, Sugino K, et al. A prospective cohort study exploring the effect of lenvatinib planned drug holidays in treatment of differentiated thyroid cancer. Thyroid. 2024;34:566–74.PubMedCrossRef
34.
Zheng X, Xu Z, Ji Q, Ge M, Shi F, Qin J, et al. A randomized, phase III study of lenvatinib in Chinese patients with radioiodine-refractory differentiated thyroid cancer. Clin Cancer Res. 2021;27:5502–9.PubMedPubMedCentralCrossRef
35.
Oh H-S, Shin DY, Kim M, Park SY, Kim TH, Kim BH, et al. Extended real-world observation of patients treated with sorafenib for radioactive iodine-refractory differentiated thyroid carcinoma and impact of lenvatinib salvage treatment: a Korean multicenter study. Thyroid. 2019;29:1804–10.PubMedCrossRef
36.
Koehler VF, Berg E, Adam P, Weber G-L, Pfestroff A, Luster M, et al. Real-world efficacy and safety of multi-tyrosine kinase inhibitors in radioiodine refractory thyroid cancer. Thyroid. 2021;31:1531–41.PubMed
37.
Brose MS, Smit JWA, Lin C-C, Tori M, Bowles DW, Worden F, et al. Multikinase inhibitors for the treatment of asymptomatic radioactive iodine-refractory differentiated thyroid cancer: global noninterventional study (RIFTOS MKI). Thyroid. 2022;32:1059–68.PubMedCrossRef
38.
Kim M, Jin M, Jeon MJ, Kim EY, Shin DY, Lim DJ, et al. Lenvatinib compared with sorafenib as a first-line treatment for radioactive iodine-refractory, progressive, differentiated thyroid carcinoma: real-world outcomes in a multicenter retrospective cohort study. Thyroid. 2023;33:91–9.PubMedCrossRef
39.
Hoftijzer H, Heemstra KA, Morreau H, Stokkel MP, Corssmit EP, Gelderblom H, et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol. 2009;161:923–31.PubMedCrossRef
40.
Ji X, Liang W, Lv G, Ding C, Lai H, Li L, et al. Efficacy and safety of targeted therapeutics for patients with radioiodine-refractory differentiated thyroid cancer: systematic review and network meta-analysis. Front Pharmacol. 2022;13: 933648.PubMedPubMedCentralCrossRef
41.
Zhang L, Feng Q, Wang J, Tan Z, Li Q, Ge M. Molecular basis and targeted therapy in thyroid cancer: progress and opportunities. BBA-Rev Cancer. 2023;1878: 188928.
42.
Yu S-T, Ge J-N, Luo J-Y, Wei Z-G, Sun B-H, Lei S-T. Treatment-related adverse effects with TKIs in patients with advanced or radioiodine refractory differentiated thyroid carcinoma: a systematic review and meta-analysis. Cancer Manag Res. 2019;11:1525–32.PubMedPubMedCentralCrossRef
43.
Aydemirli MD, Kapiteijn E, Ferrier KRM, Ottevanger PB, Links TP, Van Der Horst-Schrivers ANA, et al. Effectiveness and toxicity of lenvatinib in refractory thyroid cancer: Dutch real-life data. Eur J Endocrinol. 2020;182:131–8.PubMedCrossRef
44.
Sherman EJ, Ho AL, Fury MG, Baxi SS, Dunn L, Lee JS, et al. Combination of everolimus and sorafenib in the treatment of thyroid cancer: update on phase II study. J Clin Oncol. 2015;33:6069.CrossRef
45.
Bauman JE, Chen Z, Zhang C, Ohr JP, Ferris RL, McGorisk GM, et al. A Multicenter randomized phase II study of single agent efficacy and optimal combination sequence of everolimus and pasireotide LAR in advanced thyroid cancer. Cancers. 2022;14:2639.PubMedPubMedCentralCrossRef
46.
Chakravarty D, Santos E, Ryder M, Knauf JA, Liao X-H, West BL, et al. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest. 2011;121:4700–11.PubMedPubMedCentralCrossRef
47.
Ball DW, Jin N, Rosen DM, Dackiw A, Sidransky D, Xing M, et al. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. J Clin Endocr Metab. 2007;92:4712–8.PubMedCrossRef
48.
Leboeuf R, Baumgartner JE, Benezra M, Malaguarnera R, Solit D, Pratilas CA, et al. BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. J Clin Endocr Metab. 2008;93:2194–201.PubMedPubMedCentralCrossRef
49.
Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006;439:358–62.PubMedCrossRef
50.
Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS, et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci USA. 2010;107:14903–8.PubMedPubMedCentralCrossRef
51.
Brown SR, Hall A, Buckley HL, Flanagan L, De Castro DG, Farnell K, et al. Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial. BMC Cancer. 2019;19:582.PubMedPubMedCentralCrossRef
52.
Huillard O, Tenenbaum F, Clerc J, Goldwasser F, Groussin L. Restoring radioiodine uptake in BRAF V600E–mutated papillary thyroid cancer. J Endocr Soc. 2017;1:285–7.PubMedPubMedCentralCrossRef
53.
Jaber T, Waguespack SG, Cabanillas ME, Elbanan M, Vu T, Dadu R, et al. Targeted therapy in advanced thyroid cancer to resensitize tumors to radioactive iodine. J Clin Endocr Metab. 2018;103:3698–705.PubMedPubMedCentralCrossRef
54.
Iravani A, Solomon B, Pattison DA, Jackson P, Ravi Kumar A, Kong G, et al. Mitogen-activated protein kinase pathway inhibition for redifferentiation of radioiodine refractory differentiated thyroid cancer: an evolving protocol. Thyroid. 2019;29:1634–45.PubMedCrossRef
55.
Leboulleux S, Dupuy C, Lacroix L, Attard M, Grimaldi S, Corre R, et al. Redifferentiation of a BRAF K601E-mutated poorly differentiated thyroid cancer patient with dabrafenib and trametinib rreatment. Thyroid. 2019;29:735–42.PubMedCrossRef
56.
Jafri S, Yaqub A. Redifferentiation of BRAF V600E-mutated radioiodine refractory metastatic papillary thyroid cancer after treatment with dabrafenib and trametinib. Cureus. 2021;13: e17488.PubMedPubMedCentral
57.
Weber M, Kersting D, Riemann B, Brandenburg T, Führer-Sakel D, Grünwald F, et al. Enhancing radioiodine incorporation into radioiodine-refractory thyroid cancer with MAPK inhibition (ERRITI): a single-center prospective two-arm study. Clin Cancer Res. 2022;28:4194–202.PubMedPubMedCentralCrossRef
58.
Leboulleux S, Do Cao C, Zerdoud S, Attard M, Bournaud C, Lacroix L, et al. A phase II redifferentiation trial with dabrafenib-trametinib and 131I in metastatic radioactive iodine refractory BRAF p.V600E-mutated differentiated thyroid cancer. Clin Cancer Res. 2023;29:2401–9.PubMedCrossRef
59.
Mehnert JM, Varga A, Brose MS, Aggarwal RR, Lin C-C, Prawira A, et al. Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer. BMC Cancer. 2019;19:196.PubMedPubMedCentralCrossRef
60.
Varricchi G, Loffredo S, Marone G, Modestino L, Fallahi P, Ferrari SM. The immune landscape of thyroid cancer in the context of immune checkpoint inhibition. Int J Mol Sci. 2019;20:3934.PubMedPubMedCentralCrossRef
61.
Iyer PC, Dadu R, Gule-Monroe M, Busaidy NL, Ferrarotto R, Habra MA, et al. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J Immunother Cancer. 2018;6:68.PubMedPubMedCentralCrossRef
62.
Gunda V, Gigliotti B, Ndishabandi D, Ashry T, McCarthy M, Zhou Z, et al. Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer. Br J Cancer. 2018;119:1223–32.PubMedPubMedCentralCrossRef
63.
64.
French JD, Haugen BR, Worden FP, Bowles DW, Gianoukakis AG, Konda B, et al. Combination targeted therapy with pembrolizumab and lenvatinib in progressive, radioiodine-refractory differentiated thyroid cancers. Clin Cancer Res. 2024;30:3757–67.PubMedCrossRef
65.
Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines taskforce. Thyroid. 2006;16:109–42.PubMedCrossRef
66.
Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association Management Guidelines for patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association (ATA) guidelines taskforce on thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214.PubMedCrossRef
67.
Fugazzola L, Elisei R, Fuhrer D, Jarzab B, Leboulleux S, Newbold K, et al. 2019 European thyroid association guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer. Eur Thyroid J. 2019;8:227–45.PubMedPubMedCentralCrossRef
68.
Donohoe KJ, Aloff J, Avram AM, Bennet KG, Giovanella L, Greenspan B, et al. Appropriate use criteria for nuclear medicine in the evaluation and treatment of differentiated thyroid cancer. J Nucl Med. 2020;61:375–96.PubMedCrossRef
69.
Lebbink CA, Links TP, Czarniecka A, Dias RP, Elisei R, Izatt L, et al. 2022 European thyroid association guidelines for the management of pediatric thyroid nodules and differentiated thyroid carcinoma. Eur Thyroid J. 2022;11: e220146.PubMedPubMedCentralCrossRef
70.
Pereira MM, Williams DVL, Hallanger-Johnson DJE, Valderrabano DP. Thyroid cancer incidence trends in the United States: association with changes in professional guidelines’ recommendations. Thyroid. 2020;30:1132–40.PubMedCrossRef
71.
Gordon AJ, Dublin JC, Patel E, Papazian M, Chow MS, Persky MJ, et al. American thyroid association guidelines and national trends in management of papillary thyroid carcinoma. JAMA Otolaryngol. 2022;148:1156.
72.
Maso LD, Pierannunzio D, Francisci S, Paoli AD, Toffolutti F, Vaccarella S, et al. Trends in radioactive iodine treatment after total thyroidectomy in Italy, 2001–2018. Eur Thyroid J. 2023;12: e230051.
73.
Van Dijk D, Groen AH, Van Dijk BAC, Van Veen TL, Sluiter WJ, Links TP, et al. The outcome of treatment in differentiated thyroid cancer according to recommendations in current Dutch and American guidelines. Clin Endocrinol. 2023;98:123–30.CrossRef
74.
Tuttle RM, Ahuja S, Avram AM, Bernet VJ, Bourguet P, Daniels GH, et al. Controversies, consensus, and collaboration in the use of 131I therapy in differentiated thyroid cancer: a joint statement from the American thyroid association, the European association of nuclear medicine, the society of nuclear medicine and molecular imaging, and the European thyroid association. Thyroid. 2019;29:461–70.PubMedCrossRef
75.
Liu H, Chen Q, Liu B, Wang J, Chen C, Sun S. Blood profiles in the prediction of radioiodine refractory papillary thyroid cancer: a case–control study. J Multidiscip Health. 2023;16:535–46.CrossRef
76.
Schubert L, Mbekwe-Yepnang AM, Wassermann J, Braik-Djellas Y, Jaffrelot L, Pani F, et al. Clinico-pathological factors associated with radioiodine refractory differentiated thyroid carcinoma status. J Endocrinol Invest. 2024;47:1573–81.PubMedPubMedCentralCrossRef
77.
Meng C, Song J, Long W, Mu Z, Sun Y, Liang J, et al. A user-friendly nomogram for predicting radioiodine refractory differentiated thyroid cancer. Front Endocrinol. 2023;14:1109439.CrossRef
Metadata
Title
Research trends and hotspots of radioiodine-refractory thyroid cancer treatment in the twenty-first century: a bibliometric analysis
Authors
Yuhang Xue
Yuzhe Zhang
Xintao Ding
Xinyu Wu
Bo Li
Ye Zhang
Yongju Gao
Publication date
05-11-2024
Publisher
Springer Nature Singapore
Published in
Annals of Nuclear Medicine
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-024-01998-2